Anton Safonov
Overview
Explore the profile of Anton Safonov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
2.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Nov;
42(11):1983.
PMID: 39532066
No abstract available.
3.
Jee J, Fong C, Pichotta K, Tran T, Luthra A, Waters M, et al.
Nature
. 2024 Nov;
636(8043):728-736.
PMID: 39506116
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored...
4.
Mai N, Dos Anjos C, Razavi P, Safonov A, Patil S, Chen Y, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):92.
PMID: 39424631
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i...
5.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Oct;
42(11):1919-1935.e9.
PMID: 39393354
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. Using a large, clinically annotated cohort of patients...
6.
Safonov A, Marra A, Bandlamudi C, OLeary B, Wubbenhorst B, Ferraro E, et al.
bioRxiv
. 2024 Sep;
PMID: 39253462
The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, but their combined biologic and clinical significance has not been evaluated. To assess the role of...
7.
Pareja F, Dopeso H, Wang Y, Gazzo A, Brown D, Banerjee M, et al.
Cancer Res
. 2024 Aug;
84(20):3478-3489.
PMID: 39106449
Artificial intelligence (AI) systems can improve cancer diagnosis, yet their development often relies on subjective histologic features as ground truth for training. Herein, we developed an AI model applied to...
8.
Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1957-1980.
PMID: 38956205
Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfully...
9.
Chew S, Ferraro E, Safonov A, Chen Y, Kelly D, Razavi P, et al.
Eur J Cancer
. 2024 Jun;
207:114175.
PMID: 38896996
Background: Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) are recommended 1st line treatments in HR+HER2- metastatic breast cancer. However, the impact of prior CDK4/6i on the natural history of brain metastases...
10.
Mai N, Dos Anjos C, Razavi P, Safonov A, Patil S, Chen Y, et al.
Res Sq
. 2024 May;
PMID: 38746324
After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i...